Compare GRDN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | ANIP |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2024 | N/A |
| Metric | GRDN | ANIP |
|---|---|---|
| Price | $30.71 | $82.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $33.33 | ★ $107.33 |
| AVG Volume (30 Days) | 276.6K | ★ 574.8K |
| Earning Date | 11-10-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.28 | ★ 1.67 |
| Revenue | ★ $1,389,638,000.00 | $826,880,000.00 |
| Revenue This Year | $19.50 | $44.35 |
| Revenue Next Year | $0.48 | $11.13 |
| P/E Ratio | $108.55 | ★ $47.47 |
| Revenue Growth | 18.68 | ★ 48.87 |
| 52 Week Low | $17.78 | $54.10 |
| 52 Week High | $37.43 | $99.50 |
| Indicator | GRDN | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 49.29 |
| Support Level | $29.07 | $78.10 |
| Resistance Level | $31.11 | $86.97 |
| Average True Range (ATR) | 1.51 | 3.52 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 76.44 | 57.73 |
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.